P

Pliant Therapeutics

Develops integrin-targeted therapies for fibrosis

Vice President of Regulatory Affairs and Quality - GxP

Full-Time
$351k - $388k/yr+ Equity + Annual target bonus
Expert
Bachelor's, Master's, PharmD, PhD
South San Francisco, CA, USA
HybridThree days onsite per week in South San Francisco; travel as needed, approximately 15–20%.
Biology & BiotechRegulatory & Quality (Life Sciences)

About the job

Requirements
  • A bachelor's degree in a scientific field is required; an advanced degree such as a PhD, PharmD, or MS is preferred.
  • At least 15 years of progressive relevant Regulatory Affairs and/or Quality experience in the biotech or pharmaceutical industry, including direct oncology drug development experience.
  • At least 8 years of senior-level leadership or management experience, with direct accountability for team performance and development.
  • Demonstrated experience leading preparation and submission of INDs/CTAs and other regulatory filings, with direct ownership of early-phase oncology asset regulatory strategy, including dose-escalation and expansion trial designs.
  • Direct hands-on experience serving as the primary agency contact and leading interactions with the FDA and other global health authorities, including meetings, inspections, or submissions.
  • Working knowledge of GLP, GCP, GVP, and GMP requirements, and practical experience implementing FDA and international regulations and guidance in a development-stage environment.
  • Experience with oncology-specific regulatory designations and expedited pathways, including Fast Track, Breakthrough Therapy, Orphan Drug, and Accelerated Approval.
  • Experience managing CRO and CMO relationships, including audits, quality agreements, and vendor oversight.
  • Ability to act as both a strategic advisor to the executive team and a hands-on practitioner in a lean Phase 1/2 company.
  • Ability to travel as needed, approximately 15–20% of the time.
Responsibilities
  • Develop, own, and execute global regulatory strategy for oncology product candidates across the development lifecycle, from IND/CTA through proof-of-concept and planning for pivotal development.
  • Lead day-to-day preparation, review, and submission of regulatory filings, including INDs/CTAs, protocols, and briefing documents, in partnership with clinical development, CMC, biometrics, and translational teams.
  • Serve as primary agency contact for the FDA and other health authorities in regulatory interactions, including pre-IND, End-of-Phase 1/2, and other milestone meetings, and advocate for the company.
  • Advise the executive team on oncology-specific regulatory pathways and designations and their strategic implications for trial design and sequencing.
  • Keep executive leadership apprised of changes in the regulatory landscape affecting oncology development and provide tactical direction for cross-functional consistency in regulatory approach.
  • Oversee and lead the Quality team, providing strategic direction and managing an integrated, risk-based Quality Management System covering GLP, GCP, GVP, and GMP appropriate to a Phase 1/2 development-stage organization.
  • Ensure quality policies, procedures, and fit-for-purpose SOPs are established, understood, and followed to support IND-enabling studies, clinical trial conduct, and investigational product manufacturing and release.
  • Oversee a risk-based audit program for CROs, CMOs, clinical sites, and other third-party vendors supporting the oncology pipeline.
  • Negotiate and manage quality agreements with CMOs, CROs, partners, and suppliers.
  • Develop quality system metrics to identify and address potential compliance risks before they affect trial timelines.
  • Lead quality management and periodic dashboard reviews, and ensure development activities are not significantly disrupted by quality or compliance issues.
  • Serve as the key contact for managing and directing regulatory or quality inspections.
  • Support pharmacovigilance and safety functions as an active member of the safety governance and review team, and provide regulatory and quality input into labeling, publications, and investor or legal disclosures related to clinical and nonclinical data, as applicable.
  • Evaluate potential product and partnership opportunities in support of business development and licensing activities.
  • Own departmental planning for the combined Regulatory and Quality organization, including structure, headcount, budgeting, and systems requirements, scaling with pipeline maturity and organizational growth.
  • Lead, coach, and develop direct reports, fostering a collaborative, high-performing culture appropriate to the company's growth stage.
  • Manage relationships with external consultants and third-party service providers, including CROs, and determine when and how to engage external support as the organization scales.
Desired Qualifications
  • Experience with small-molecule and/or targeted therapy development programs.
  • Prior experience building or scaling a Regulatory and Quality function to support a growing clinical-stage company.
  • Prior experience in an organization transitioning from Phase 1b/2 to late-stage development, including scaling regulatory and quality systems for pivotal trials.

About the company

Pliant Therapeutics develops drugs to treat fibrotic diseases. The company focuses on inhibiting integrin pathways involved in tissue scarring to stop disease progression and potentially restore normal organ function. Its products work by targeting fibrosis-related mechanisms at the molecular level, guided by medicinal chemistry and advanced screening technologies, and advancing candidates through clinical trials toward commercialization. Pliant differentiates itself through deep expertise in integrin biology and fibrosis, aiming to create best-in-class therapies that can address multiple fibrotic indications and provide targeted, effective treatments. The company’s goal is to transform the treatment of fibrotic diseases by halting progression and reversing fibrosis, improving patient outcomes and organ function.

Company Size

51-200

Company Stage

IPO

Headquarters

South San Francisco, California

Founded

2015

Get referred to Pliant Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FORTIFY enrolled its first patient on April 30, 2026, validating execution.
  • Second-quarter 2026 cash reached $159.6 million, funding operations into 2028.
  • Updated April 2026 data showed responses in checkpoint-refractory tumors, supporting combination potential.

What critics are saying

  • Bexotegrast died in IPF in 2025 after unfavorable risk-benefit and adverse events.
  • Headcount fell to roughly 52 by March 2026, showing a depleted organization.
  • Pliant now lives or dies on PLN-101095; a 2027 failure threatens the company.

What makes Pliant Therapeutics unique

  • PLN-101095 targets αvβ8 and αvβ1, attacking TGF-β activation in tumors directly.
  • Pliant repurposed integrin chemistry from fibrosis into oncology after BEACON-IPF collapse.
  • Fast Track on August 18, 2026 signals FDA recognition for a differentiated checkpoint-resistance strategy.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Company Match
  • Remote Work Options
  • Flexible Work Hours
  • Professional Development Budget
  • Wellness Program
  • Mental Health Support
  • Gym Membership

Growth & Insights and Company News

Headcount

6 month growth

9%

1 year growth

8%

2 year growth

-1%
Yahoo Finance
Sep 30th, 2026
Pliant Therapeutics appoints David Raben as chief medical officer

Pliant Therapeutics has appointed David Raben as chief medical officer. Dr Raben brings over 30 years of experience in academic translational research, clinical care, and oncology drug development. Dr Raben is a board-certified radiation oncologist. Most recently, he served as chief medical officer at Bicara Therapeutics, where he oversaw clinical development of the company's lead asset across multiple indications. Previously, he held senior positions at Amgen and Genentech, leading oncology programmes and clinical strategy. Before moving to industry, Dr Raben spent more than 20 years as a professor at the University of Colorado Cancer Center. His research focused on combining novel biologic therapies with radiation for patients with advanced cancers. Pliant is developing PLN-101095, a dual-selective inhibitor being investigated for treating solid tumours.

Associated Press
Aug 11th, 2026
Pliant Therapeutics reports strong enrollment in FORTIFY Phase 1b oncology trial, appoints two directors

Pliant Therapeutics reported second quarter 2026 financial results and announced the appointment of two oncology drug development experts to its board of directors. The clinical-stage biotechnology company appointed Flavia Borellini and Robert Iannone, who bring extensive experience in global oncology drug development and commercialisation. The company is experiencing strong enrollment in FORTIFY, a Phase 1b trial of PLN-101095 in combination with pembrolizumab for immune checkpoint inhibitor-refractory advanced or metastatic solid tumours. The trial will enroll up to 102 patients across three cohorts, with interim data expected in 2027. Research and development expenses decreased to $16.7 million from $32.2 million year-over-year. Net loss fell to $22.4 million from $43.3 million in the prior-year quarter. As of 30 June 2026, Pliant had cash and investments of $159.6 million, expected to fund operations into the second half of 2028.

GlobeNewswire
May 21st, 2026
Pliant Therapeutics announces upcoming presentation at the 2026 American Society of Clinical Oncology Annual Meeting.

Pliant Therapeutics announces upcoming presentation at the 2026 American Society of Clinical Oncology Annual Meeting. Highlights FORTIFY, the Phase 1b indication expansion trial of PLN-101095 enrolling patients with ICI-refractory solid tumors SOUTH SAN FRANCISCO, Calif., May 21, 2026 (GLOBE NEWSWIRE) - Pliant Therapeutics, Inc. (Nasdaq: PLRX) today announced a presentation at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, Illinois from May 29 to June 2, 2026. Poster Presentation | Presenter: | Timothy A. Yap, MBBS, Ph.D., University of Texas, M.D. Anderson Cancer Center | | Session: | Developmental Therapeutics - Immunotherapy | | Date: | Saturday, May 30, 2026, 1:30 - 4:30 p.m. Central Time | | Location: | Hall A, Poster 467b | FORTIFY - PLN-101095 Phase 1b Indication Expansion Trial PLN-101095 is currently being evaluated in Phase 1a/1b open-label, dose-escalation and indication expansion trial (NCT06270706) to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095 when administered orally in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. Pliant is currently enrolling patients in FORTIFY, a Phase 1b open-label, indication expansion trial enrolling three cohorts of patients with non-small cell lung cancer (NSCLC), tumors with high tumor mutational burden or clear cell renal cell carcinoma. Patients will be treated for 14 days with PLN-101095 dosed at 1,000 mg twice daily as monotherapy, after which pembrolizumab will be added as combination therapy. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. Pliant's lead program is PLN-101095, an oral, small molecule, dual-selective inhibitor of α[v] ß[8] and α[v] ß[1] integrins, that is being developed for the treatment of ICI-refractory advanced or metastatic solid tumors. PLN-101095 is being investigated in FORTIFY, a Phase 1b indication expansion trial enrolling patients with NSCLC, tumors with high tumor mutational burden or clear cell renal cell carcinoma. Pliant's preclinical research is focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules with programs focused on delivering siRNAs to skeletal muscle cells, adipocytes, and renal cells. For additional information on Pliant, visit www.PliantRx.com and follow us on X, LinkedIn and Facebook. Investor and Media Contact: Christopher Keenan Vice President, Investor Relations and Corporate Communications Pliant Therapeutics, Inc. [email protected]

The Globe and Mail
Mar 18th, 2026
Pliant Therapeutics announces upcoming presentation of Phase 1 clinical trial of PLN-101095 in patients with solid tumors at the 2026 AACR Annual Meeting.

Pliant Therapeutics announces upcoming presentation of Phase 1 clinical trial of PLN-101095 in patients with solid tumors at the 2026 AACR Annual Meeting. Pliant Therapeutics, Inc. - GlobeNewswire - Wed Mar 18, 8:00AM CDT SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) - Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026. The abstract was selected for oral presentation as part of the Clinical Trials Mini Symposium. Oral Presentation Title: First-in-human phase I study of PLN-101095, a first-in-class dual α[v] β[8] /α[v] β[1] integrin inhibitor, as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors refractory to immune checkpoint inhibitors (ICI) Presenter: Timothy A. Yap, M.D., Ph.D., University of Texas, M.D. Anderson Cancer Center Session: CTMS01: Updates in Anticancer Immunotherapies Date: Saturday, April 18, 2026 Presentation Time: 10:21 a.m. - 10:31 a.m. Pacific Time Location: Ballroom 6A - Upper Level - San Diego Convention Center Oncology Program PLN-101095 is an oral, small molecule, dual selective inhibitor of αvβ8 and αvβ1 integrins designed to overcome checkpoint resistance by blocking TGF-β activation in the tumor microenvironment. Pliant is currently conducting a Phase 1a/1b open-label, dose-escalation and indication expansion trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary evidence of antitumor activity of PLN-101095, as monotherapy and in combination with pembrolizumab, in patients with immune checkpoint inhibitor (ICI)-refractory advanced or metastatic solid tumors. About Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery and development of integrin-based therapeutics. The Company's lead program is PLN-101095, a small molecule, dual-selective inhibitor of αvß8 and αvß1 integrins, that is being developed for the treatment of solid tumors. Pliant's early-stage platform includes preclinical research focused on tissue-specific delivery and internalization of drug payloads utilizing integrin receptor-binding molecules. For additional information, please visit: www.PliantRx.com. Follow us on social media X, LinkedIn and Facebook. Investor and Media Contact: Christopher Keenan Vice President, Investor Relations and Corporate Communications Pliant Therapeutics, Inc. [email protected] This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Associated Press
Mar 11th, 2026
Pliant Therapeutics' PLN-101095 shows deep responses in checkpoint inhibitor refractory tumors

Pliant Therapeutics has raised $120 million in a Series C round, valuing the company at $1.45 billion, as it advances PLN-101095, an oral inhibitor targeting checkpoint-resistant cancers. Phase 1 data showed four responses, including one complete response, in 10 heavily pretreated immune checkpoint inhibitor-refractory patients. Responding patients showed significant increases in plasma interferon gamma after 14 days of PLN-101095 monotherapy before adding pembrolizumab. The company has initiated a Phase 1b indication expansion trial across non-small cell lung cancer, clear cell renal cell carcinoma and high tumour mutational burden cancers. First patient enrolment is anticipated in the second quarter, with interim data expected in 2027. Pliant reported $192.4 million in cash and investments as of December 31, 2025, sufficient to fund operations into the second half of 2028.